Cargando…

Psychopathological Dimensions in Portuguese Subjects with Transthyretin Familial Amyloid Polyneuropathy

BACKGROUND: Transthyretin familial amyloid polyneuropathy (TTR-FAP) is a fatal, chronic, progressive disease. It is a rare hereditary amyloidosis, which manifests as a sensorimotor neuropathy and autonomic dysfunction. It begins during adulthood. AIMS AND METHODS: Our aim is to evaluate psychopathol...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lopes, Alice, Fonseca, Isabel, Sousa, Alexandra, Branco, Margarida, Rodrigues, Carla, Coelho, Teresa, Sequeiros, Jorge, Freitas, Paula
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6945894/ https://www.ncbi.nlm.nih.gov/pubmed/31988916 http://dx.doi.org/10.1159/000485118

Ejemplares similares

Psychopathological dimensions in familial amyloid polyneuropathy patients
por: Lopes, Alice, et al.
Publicado: (2015)

Life paths of familial amiloidotic polyneuropathy patients: a descriptive study
por: Lopes, Alice, et al.
Publicado: (2015)

Epidemiology of transthyretin familial amyloid polyneuropathy in Portugal
por: Inês, Mónica, et al.
Publicado: (2015)

The rehabilitation in the management of Transthyretin Familial Amyloid Polyneuropathy
por: Morier, Agnès, et al.
Publicado: (2015)

Transthyretin interacts with actin regulators in a Drosophila model of familial amyloid polyneuropathy
por: I. Oliveira da Silva, Marina, et al.
Publicado: (2020)

Transthyretin familial amyloid polyneuropathy impact on health-related quality of life
por: Inês, Mónica, et al.
Publicado: (2015)

Ocular manifestations of transthyretin-related familial amyloid polyneuropathy
por: Rousseau, Antoine, et al.
Publicado: (2015)

Tafamidis for a Transplant Patient with Transthyretin Amyloid Polyneuropathy
por: Romero-Imbroda, Jesús, et al.
Publicado: (2017)

Estimating the global prevalence of transthyretin familial amyloid polyneuropathy
por: Schmidt, Hartmut H., et al.
Publicado: (2018)

Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy
por: Coelho, Teresa, et al.
Publicado: (2013)

First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy
por: Adams, David, et al.
Publicado: (2016)

Vasculopathy in transthyretin Val30Met familial amyloid polyneuropathy
por: Koike, Haruki, et al.
Publicado: (2015)

Ophtalmologic changes in transthyretin familial amyloid polyneuropathy (ATTR-FAP)
por: Ferreira, Natália
Publicado: (2015)

“Red‐flag” symptom clusters in transthyretin familial amyloid polyneuropathy
por: Conceição, Isabel, et al.
Publicado: (2016)

Management of asymptomatic gene carriers of transthyretin familial amyloid polyneuropathy
por: Schmidt, Hartmut H.‐J., et al.
Publicado: (2016)

Nerve Ultrasound Comparison Between Transthyretin Familial Amyloid Polyneuropathy and Chronic Inflammatory Demyelinating Polyneuropathy
por: Du, Kang, et al.
Publicado: (2021)

Familial amyloid polyneuropathy in Portugal: New genes modulating age‐at‐onset
por: Santos, Diana, et al.
Publicado: (2016)

Genotype–phenotype correlation and course of transthyretin familial amyloid polyneuropathies in France
por: Mariani, Louise‐Laure, et al.
Publicado: (2015)

Transthyretin familial amyloid polyneuropathy (TTR‐FAP): Parameters for early diagnosis
por: Escolano‐Lozano, Fabiola, et al.
Publicado: (2017)

Impact of Non-Cardiac Clinicopathologic Characteristics on Survival in Transthyretin Amyloid Polyneuropathy
por: González‐Duarte, Alejandra, et al.
Publicado: (2020)

Clinical and genetic features of transthyretin-related familial amyloid polyneuropathy in China
por: Liu, Lei, et al.
Publicado: (2020)

Patterns of myelinated nerve fibers loss in transthyretin amyloid polyneuropathy and mimics
por: Du, Kang, et al.
Publicado: (2022)

Specific ophtalmologic changes in late onset familial amyloid polyneuropathy (FAP) portuguese patients
por: Ferreira, Natalia, et al.
Publicado: (2015)

Red flags and adjusted suspicion index for distinguishing hereditary transthyretin amyloid polyneuropathy from idiopathic axonal polyneuropathy
por: Warendorf, Janna K., et al.
Publicado: (2023)

Clinical, epidemiological, genetic, and electrophysiological characteristics of transthyretin familial amyloid polyneuropathies in Israel
por: Sadeh, Menachem, et al.
Publicado: (2015)

Inflammatory state exists in familial amyloid polyneuropathy that may be triggered by mutated transthyretin
por: Suenaga, Genki, et al.
Publicado: (2017)

Prevalence of hereditary transthyretin amyloid polyneuropathy in idiopathic progressive neuropathy in conurban areas
por: Thimm, Andreas, et al.
Publicado: (2019)

Repurposing Benzbromarone for Familial Amyloid Polyneuropathy: A New Transthyretin Tetramer Stabilizer
por: Cotrina, Ellen Y., et al.
Publicado: (2020)

Vagus nerve ultrasound in transthyretin familial amyloid polyneuropathy: A pilot study
por: Du, Kang, et al.
Publicado: (2021)

The hidden story behind gender differences in familial amyloid polyneuropathy (FAP) ATTRV30M
por: Santos, Diana, et al.
Publicado: (2015)

Optimizing the management of transthyretin familial amyloid polyneuropathy in Europe: early diagnosis and effective care
por: Adams, David
Publicado: (2016)

Updated Evaluation of the Safety, Efficacy and Tolerability of Tafamidis in the Treatment of Hereditary Transthyretin Amyloid Polyneuropathy
por: Falcão de Campos, Catarina, et al.
Publicado: (2023)

C1QA and C1QC modify age‐at‐onset in familial amyloid polyneuropathy patients
por: Dias, Andreia, et al.
Publicado: (2019)

Vitreous Amyloidosis as the Presenting Symptom of Familial Amyloid Polyneuropathy TTR Val30Met in a Portuguese Patient
por: Seca, Mariana, et al.
Publicado: (2014)

Feasibility of assessing progression of transthyretin amyloid polyneuropathy using nerve conduction studies: Findings from the Transthyretin Amyloidosis Outcomes Survey (THAOS)
por: Waddington‐Cruz, Márcia, et al.
Publicado: (2021)

Positive real-world effectiveness of tafamidis for delaying disease progression in transthyretin familial amyloid polyneuropathy
por: Stewart, Michelle, et al.
Publicado: (2015)

Post Hoc Analysis of Nutritional Status in Patients with Transthyretin Familial Amyloid Polyneuropathy: Impact of Tafamidis
por: Suhr, Ole B., et al.
Publicado: (2014)

Epidemiological and clinical characteristics of symptomatic hereditary transthyretin amyloid polyneuropathy: a global case series
por: Waddington-Cruz, Márcia, et al.
Publicado: (2019)

Cardiomyopathy correlates to nerve damage in p.A117S late‐onset transthyretin amyloid polyneuropathy
por: Lin, Yen‐Hung, et al.
Publicado: (2022)

Hereditary Transthyretin Amyloidosis with Polyneuropathy: Monitoring and Management
por: Vélez-Santamaría, Valentina, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rjgh7musv8arluer5oe90neuf4